The TRACTION-2 clinical research trial is evaluating an investigational product called GFB-887 for the potential treatment of focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), and diabetic nephropathy (DN). The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to their kidney disease.
You can find out if you may qualify to take part in TRACTION-2 by answering a few questions. Depending on your answers, you may be referred to a trial site for screening.
Your doctor can also help you find out if you may qualify for TRACTION-2. You can give your doctor the clinicaltrials.gov reference number: NCT04387448.
Patients with progressive kidney disease may benefit from therapeutic options tailored to their specific conditions. Clinical trials are researching options that may have the potential to slow disease progression and preserve kidney function for these patients.
GFB-887 is an oral investigational product that has not been approved for any use by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
Kidney diseases like focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), and diabetic nephropathy (DN) are progressive, meaning they get worse over time. It is believed that this worsening of disease results from special kidney cells called podocytes being injured. Researchers are looking to see if GFB-887 may help slow or halt progression of kidney failure by preventing podocyte injury.
TRACTION-2 is a clinical research trial for people with kidney disease, specifically focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), or diabetic nephropathy (DN). The purpose of this trial is to determine if the investigational product (GFB-887) is safe and may help people with high levels of protein in their urine due to their kidney disease.
The following is only a summary. Additional details are provided in the Trial FAQs. The trial doctor or trial staff will also explain all aspects of the trial to you and answer your questions.
1. Informed consent process
(decide if you want to take part in the trial)
Even if you choose to take part in the trial and sign the consent form, you are still free to leave the trial at any time without giving a reason.
2. Screening
(find out if you qualify to take part in the trial)
3. Taking part in the trial
To begin the process of finding out if you may qualify to take part in TRACTION-2, click the box for any of the following statements that apply to you.
You may be a potential candidate for this trial.
NextThe TRACTION-2 trial is happening at sites across the United States. Trial sites may continue to be added. Click a pin on the map or select a location from the list to view site information.